Latest Evolution in Neurological Biomarker

A biomarker is an indicator of normal biological processes, pathogenic processes, or evaluating a therapeutic intervention. Thus, the discovery of biomarker is an active research area, where a few biomarkers have been sufficiently studied and validated for its use in clinical practice and clinical trials.

Biomarkers are disease-specific molecular indicators. In early days, the neurological disease biomarkers were not that accessible; however, the advancements in the technology have enabled the measurement of specific biomarkers for tracking the health of the brain. This helps in the early detection of a disease and less invasive diagnostics, and enables faster drug development.

Get Sample Copy of this Study

Companies Involved:

1. Thermo Fisher Scientific Inc.
2. Abbott
3. Myriad Genetics, Inc.
4. Bio-Rad Laboratories Inc.
5. QIAGEN
6. Banyan Biomarkers, Inc
7. Immunarray Pvt. Ltd.
8. Quest Diagnostics Incorporated
9. Perkin Elmer, Inc.
10. MERCK KGaA

Rapid developments in healthcare and drug discovery sector are leading to the introduction of new therapeutic solutions for the treatment of neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage the research activities and find a remedy for neurological disease treatment.

The National Institute of Neurological Disorders and Stroke (NINDS) biomarker program is focused on enhancing the quality and efficiency of neurotherapeutic clinical research and supports the biomarker validation. The program promotes rigorous biomarker identification and validation by providing funds for the research activities. Similarly, Parkinson’s Disease Biomarkers Program (PDBP) was initiated to support new and existing research promoting the discovery of biomarker for Parkinson's disease.